BioVie has hailed phase 2 data as evidence that bezisterim could represent a “meaningful advance” in the treatment of Parkinson’s disease. But the biotech focused on a new composite measure, rather than its stated primary endpoint, and emphasized outcomes in a subpopulation of patients.
